Maria Luisa Brandi

List of Publications by Year
in descending order

179 papers	12,993 citations	50276 46 h-index	24982 109 g-index
202 all docs	202 docs citations	202 times ranked	12480 citing authors

#	Article	IF	Citations
1	CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5658-5671.	3.6	1,782
2	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3561-3569.	3.6	1,277
3	Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2990-3011.	3.6	1,127
4	Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. New England Journal of Medicine, 2017, 377, 1417-1427.	27.0	901
5	Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. Journal of Bone and Mineral Research, 2011, 26, 2317-2337.	2.8	485
6	Oxidative stress in bone remodeling: role of antioxidants. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 209.	1.0	467
7	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	3.4	414
8	Osteogenic Differentiation of Human Adipose Tissue-Derived Stem Cells Is Modulated by the miR-26a Targeting of the SMAD1 Transcription Factor. Journal of Bone and Mineral Research, 2008, 23, 287-295.	2.8	333
9	Management of Hypoparathyroidism: Summary Statement and Guidelines. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2273-2283.	3.6	303
10	Vascular Biology and the Skeleton. Journal of Bone and Mineral Research, 2006, 21, 183-192.	2.8	267
11	Efficacy and safety of recombinant human parathyroid hormone (1â€“84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes and Endocrinology,the, 2013, 1, 275-283.	11.4	244
12	The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nature Reviews Endocrinology, 2019, 15, 33-51.	9.6	226
13	Effects of Dairy Products Consumption on Health: Benefits and Beliefsâ€”A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Calcified Tissue International, 2016, 98, 1-17.	3.1	210
14	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritisâ€”From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 2016, 45, S3-S11.	3.4	203
15	Guidelines for the management of osteoporosis and fragility fractures. Internal and Emergency Medicine, 2019, 14, 85-102.	2.0	198
16	Management of Hypoparathyroidism: Present and Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2313-2324.	3.6	151
17	Microarchitecture, the key to bone quality. Rheumatology, 2009, 48, iv3-iv8.	1.9	147
18	Pancreatectomy in Multiple Endocrine Neoplasia Type 1-Related Gastrinomas and Pancreatic Endocrine Neoplasias. Annals of Surgery, 2006, 244, 61-70.	4.2	131

#	Article	IF	Citations
19	The role of calcium supplementation in healthy musculoskeletal ageing. Osteoporosis International, 2017, 28, 447-462.	3.1	130
20	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 2017, 28, 2023-2034.	3.1	126
21	Calcium sensing receptor signalling in physiology and cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1732-1744.	4.1	123
22	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International, 2017, 28, 767-774.	3.1	113
23	Calcium Intake in Bone Health: A Focus on Calcium-Rich Mineral Waters. Nutrients, 2018, 10, 1930.	4.1	108
24	Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcified Tissue International, 2019, 105, 271-284.	3.1	102
25	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 2016, 28, 47-58.	2.9	91
26	Multiple endocrine neoplasia type 1 (MEN1): Not only inherited endocrine tumors. Genetics in Medicine, 2009, 11, 825-835.	2.4	89
27	Epigenetic Mechanisms in Bone Biology and Osteoporosis: Can They Drive Therapeutic Choices?. International Journal of Molecular Sciences, 2016, 17, 1329.	4.1	87
28	Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocrine Reviews, 2021, 42, 133-170.	20.1	85
29	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. European Journal of Endocrinology, 2019, 180, P1-P22.	3.7	81
30	The Negative Feedback-Loop between the Oncomir Mir-24-1 and Menin Modulates the Men1 Tumorigenesis by Mimicking the â€œKnudsonâ€™s Second Hitâ€• PLoS ONE, 2012, 7, e39767.	2.5	81
31	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017, 58, 349-359.	2.3	77
32	The calcium-sensing receptor in bone metabolism: from bench to bedside and back. Osteoporosis International, 2015, 26, 2055-2071.	3.1	75
33	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International, 2019, 30, 2155-2165.	3.1	69
34	Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clinical and Experimental Research, 2020, 32, 547-560.	2.9	65
35	Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome â€“ An International Consensus Statement. Neuroendocrinology, 2021, 111, 609-630.	2.5	63
36	Glutathione, N-acetylcysteine and Lipoic Acid Down-Regulate Starvation-Induced Apoptosis, RANKL/OPG Ratio and Sclerostin in Osteocytes: Involvement of JNK and ERK1/2 Signalling. Calcified Tissue International, 2015, 96, 335-346.	3.1	62

#	Article	IF	Citations
37	Vitamin K and Osteoporosis. Nutrients, 2020, 12, 3625.	4.1	62
38	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, 36, 2811-2824.	2.9	60
39	Functional epithelial cell line cloned from rat parathyroid glands.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 3269-3273.	7.1	58
40	Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporosis International, 2019, 30, 391-402.	3.1	56
41	Characterization, regulation, and function of specific cell membrane receptors for insulin-like growth factor I on bone endothelial cells. Journal of Bone and Mineral Research, 1994, 9, 329-337.	2.8	53
42	Gaucher Disease and Bone Manifestations. Calcified Tissue International, 2014, 95, 477-494.	3.1	53
43	The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine, 2015, 50, 12-26.	2.3	53
44	A heterozygous frameshift mutation in exon 1 of CDKN1B gene in a patient affected by MEN4 syndrome. European Journal of Endocrinology, 2014, 171, K7-K17.	3.7	52
45	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017, 56, 245-261.	2.3	52
46	Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality. Trends in Endocrinology and Metabolism, 2020, 31, 918-927.	7.1	46
47	MEN1 gene mutation analysis in Italian patients with multiple endocrine neoplasia type 1. European Journal of Endocrinology, 2000, 142, 131-137.	3.7	42
48	In VitroEffects of Strontium on Proliferation and Osteoinduction of Human Preadipocytes. Stem Cells International, 2015, 2015, 1-12.	2.5	42
49	Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone, 2015, 79, 143-149.	2.9	42
50	Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery?. Clinics, 2012, 67, 141-144.	1.5	41
51	Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism. Journal of Endocrinological Investigation, 2015, 38, 577-593.	3.3	41
52	MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. European Journal of Endocrinology, 2019, 180, R37-R44.	3.7	41
53	Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1). Endocrine, 2016, 52, 495-506.	2.3	40
54	Bone management in hematologic stem cell transplant recipients. Osteoporosis International, 2018, 29, 2597-2610.	3.1	39

#	Article	IF	Citations
55	Early post-surgical cognitive dysfunction is a risk factor for mortality among hip fracture hospitalized older persons. Osteoporosis International, 2017, 28, 667-675.	3.1	37
56	Rare causes of osteoporosis. Clinical Cases in Mineral and Bone Metabolism, 2015, 12, 151-6.	1.0	36
57	The Regulatory Network Menin-MicroRNA 26a As a Possible Target for RNA-Based Therapy of Bone Diseases. Nucleic Acid Therapeutics, 2012, 22, 103-108.	3.6	35
58	Fracture prevention service to bridge the osteoporosis care gap. Clinical Interventions in Aging, 2015, 10, 1035.	2.9	35
59	MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors. Endocrine, 2018, 59, 438-448.	2.3	33
60	Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 2022, 34, 695-714.	2.9	33
61	Clinical presentation and management of patients with primary hyperparathyroidism in Italy. Journal of Endocrinological Investigation, 2018, 41, 1339-1348.	3.3	32
62	Phosphate wasting disorders in adults. Osteoporosis International, 2018, 29, 2369-2387.	3.1	32
63	Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial. Journal of Bone and Mineral Research, 2020, 36, 1967-1978.	2.8	32
64	Taxonomy of rare genetic metabolic bone disorders. Osteoporosis International, 2015, 26, 2529-2558.	3.1	31
65	Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Osteoporosis International, 2017, 28, 3239-3249.	3.1	31
66	X-linked hypophosphatemic rickets: an Italian expertsâ€™ opinion survey. Italian Journal of Pediatrics, 2019, 45, 67.	2.6	31
67	The Involvement of Long Non-Coding RNAs in Bone. International Journal of Molecular Sciences, 2021, 22, 3909.	4.1	31
68	The Epidemiology of Hypoparathyroidism in Italy: An 8-Year Register-Based Study. Calcified Tissue International, 2017, 100, 278-285.	3.1	30
69	Surgical management of chordoma: A systematic review. Journal of Spinal Cord Medicine, 2020, 43, 797-812.	1.4	30
70	Blueberry Juice Antioxidants Protect Osteogenic Activity against Oxidative Stress and Improve Long-Term Activation of the Mineralization Process in Human Osteoblast-Like SaOS-2 Cells: Involvement of SIRT1. Antioxidants, 2020, 9, 125.	5.1	29
71	Understanding osteoporotic pain and its pharmacological treatment. Osteoporosis International, 2018, 29, 1477-1491.	3.1	28
72	Surgery for multiple endocrine neoplasia type 1-related insulinoma: long-term outcomes in a large international cohort. British Journal of Surgery, 2020, 107, 1489-1499.	0.3	28

#	Article	IF	Citations
73	Edema-like marrow signal intensity: a narrative review with a pictorial essay. Skeletal Radiology, 2021, 50, 645-663.	2.0	28
74	Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients. Orphanet Journal of Rare Diseases, 2018, 13, 205.	2.7	27
75	Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). American Journal of Human Genetics, 1993, 53, 1167-72.	6.2	27
76	Natpara for the treatment of hypoparathyroidism. Expert Opinion on Biological Therapy, 2016, 16, 1417-1424.	3.1	25
77	Clinical presentation and management of hypoparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 927-939.	4.7	25
78	Microencapsulation of Human Parathyroid Cells: An â€œin Vitroâ€•Study. Journal of Surgical Research, 2001, 96, 81-89.	1.6	24
79	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Calcified Tissue International, 2018, 103, 151-163.	3.1	23
80	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine, 2018, 62, 215-233.	2.3	21
81	Causes and pathophysiology of hypoparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 909-925.	4.7	21
82	Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 171-183.	5.7	21
83	Prevalence of Chronic Hypoparathyroidism in a Mediterranean Region as Estimated by the Analysis of Anonymous Healthcare Database. Calcified Tissue International, 2018, 103, 144-150.	3.1	20
84	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: New and future perspectives for parathyroid carcinoma. Endocrine-Related Cancer, 2020, 27, T53-T63.	3.1	20
85	Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent. Current Medical Research and Opinion, 2013, 29, 1565-1572.	1.9	19
86	Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism. Expert Opinion on Drug Safety, 2017, 16, 617-625.	2.4	19
87	Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1. International Journal of Molecular Sciences, 2021, 22, 4041.	4.1	19
88	Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas. American Journal of Translational Research (discontinued), 2017, 9, 1743-1753.	0.0	19
89	Genetics of Primary Hyperparathyroidism. Urologia Internationalis, 2004, 72, 11-16.	1.3	18
90	Muscle endocrinology and its relation with nutrition. Aging Clinical and Experimental Research, 2019, 31, 783-792.	2.9	18

#	Article	IF	Citations
91	Improving patient outcomes in fibrous dysplasia/McCune-Albright syndrome: an international multidisciplinary workshop to inform an international partnership. Archives of Osteoporosis, 2017, 12, 21.	2.4	17
92	Characterization of Skeletal Muscle Endocrine Control in an In Vitro Model of Myogenesis. Calcified Tissue International, 2020, 107, 18-30.	3.1	17
93	Bone status in genetic syndromes: A review. Hormones, 2015, 14, 19-31.	1.9	15
94	Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset. Osteoporosis International, 2015, 26, 2695-2702.	3.1	15
95	Estrogen inhibits starvationâ€induced apoptosis in osteocytes by a redoxâ€independent process involving association of <scp>JNK</scp> and glutathione Sâ€transferase P1â€1. FEBS Open Bio, 2017, 7, 705-718.	2.3	15
96	Skeletal System Biology and Smoke Damage: From Basic Science to Medical Clinic. International Journal of Molecular Sciences, 2021, 22, 6629.	4.1	15
97	Available In Vitro Models for Human Satellite Cells from Skeletal Muscle. International Journal of Molecular Sciences, 2021, 22, 13221.	4.1	15
98	Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breastâ€“ovarian cancer syndromes: a case report. Cancer Genetics and Cytogenetics, 2009, 195, 75-79.	1.0	14
99	Protective role of benzoselenophene derivatives of resveratrol on the induced oxidative stress in intestinal myofibroblasts and osteocytes. Chemico-Biological Interactions, 2017, 275, 13-21.	4.0	14
100	Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. Journal of Bone Oncology, 2021, 28, 100361.	2.4	14
101	Indications on the use of vitamin D and vitamin D metabolites in clinical phenotypes. Clinical Cases in Mineral and Bone Metabolism, 2010, 7, 243-50.	1.0	14
102	What Is the Relationship Between Paget's Disease of Bone and Hyperparathyroidism?. Journal of Bone and Mineral Research, 2006, 21, P69-P74.	2.8	13
103	In VitroBehavior of Human Adipose Tissue-Derived Stem Cells on Poly(Îµ-caprolactone) Film for Bone Tissue Engineering Applications. BioMed Research International, 2015, 2015, 1-12.	1.9	13
104	An autoregulatory network between menin and pri-miR-24-1 is required for the processing of its specific modulator miR-24-1 in BON1 cells. Molecular BioSystems, 2016, 12, 1922-1928.	2.9	13
105	Calcium-Sensing Receptor Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1: Epitopes, Specificity, Functional Affinity, IgG Subclass, and Effects on Receptor Activity. Journal of Immunology, 2018, 201, 3175-3183.	0.8	12
106	Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259.	3.3	11
107	Chronic hypoparathyroidism and treatment with teriparatide. Endocrine, 2021, 72, 249-259.	2.3	11
108	Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e783-e792.	3.6	11

#	Article	IF	Citations
109	The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 123.	1.0	11
110	Parathyroid Tumors: Molecular Signatures. International Journal of Molecular Sciences, 2021, 22, 11206.	4.1	11
111	The gaps between patient and physician understanding of the emotional and physical impact of osteoporosis. Archives of Osteoporosis, 2010, 5, 145-153.	2.4	10
112	When Parathyroidectomy Should Be Indicated or Postponed in Adolescents With MEN1-Related Primary Hyperparathyroidism. Frontiers in Endocrinology, 2018, 9, 597.	3.5	10
113	Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy. Cells, 2021, 10, 1895.	4.1	10
114	Circulating MicroRNAs as Biomarkers of Osteoporosis and Fragility Fractures. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2267-2285.	3.6	10
115	MEN1 family with a novel frameshift mutation. Journal of Endocrinological Investigation, 2006, 29, 450-456.	3.3	9
116	Bone status of children born from mothers with autoimmune diseases treated during pregnancy with prednisone and/or low molecular weight heparin. Pediatric Rheumatology, 2014, 12, 47.	2.1	9
117	Clinical Presentation of Hypoparathyroidism. Frontiers of Hormone Research, 2019, 51, 139-146.	1.0	9
118	Multiple Endocrine Neoplasia Type 1: The Potential Role of microRNAs in the Management of the Syndrome. International Journal of Molecular Sciences, 2020, 21, 7592.	4.1	9
119	Bone tissue and mineral metabolism in hereditary endocrine tumors: clinical manifestations and genetic bases. Orphanet Journal of Rare Diseases, 2020, 15, 102.	2.7	9
120	Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy. International Journal of Molecular Sciences, 2021, 22, 7352.	4.1	9
121	Human Adipose Tissue-Derived Stem Cells and a Poly(Îµ-Caprolactone) Scaffold Produced by Computer-Aided Wet Spinning for Bone Tissue Engineering. Journal of Biomaterials and Tissue Engineering, 2017, 7, 622-633.	0.1	9
122	Muscle Physiopathology in Parathyroid Hormone Disorders. Frontiers in Medicine, 2021, 8, 764346.	2.6	9
123	Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review. Osteoporosis International, 2022, 33, 2467-2478.	3.1	9
124	A registry for patients with chronic hypoparathyroidism in Russian adults. Endocrine Connections, 2020, 9, 627-636.	1.9	8
125	Bone Marrow Edema. Journal of Bone and Joint Surgery - Series A, 2022, 104, 189-200.	3.0	8
126	An overview of osteoporosis: from genetics to clinics. Aging Clinical and Experimental Research, 2011, 23, 3-5.	2.9	8

#	Article	IF	Citations
127	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. Nutrients, 2022, 14, 1742.	4.1	8
128	The genetic ascertainment of multiple endocrine neoplasia type 1 syndrome by ancient DNA analysis. Journal of Endocrinological Investigation, 2008, 31, 905-909.	3.3	7
129	Comparison of bone mass and quality determinants in adolescents and young adults with juvenile systemic lupus erythematosus (JSLE) and juvenile idiopathic arthritis (JIA). Lupus, 2014, 23, 1392-1406.	1.6	7
130	Quality of life in Italian patients with Multiple endocrine neoplasia type 1 (MEN 1): results of an extensive survey. Orphanet Journal of Rare Diseases, 2021, 16, 16.	2.7	7
131	Evidence of a possible therapeutic role of vitamin D in a cohort of adult Caucasian vitiligo patients. International Journal for Vitamin and Nutrition Research, 2020, 90, 200-204.	1.5	7
132	The use of cholecalciferol in patients with hip fracture. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 48.	1.0	7
133	Management of post-menopausal osteoporosis: Something new on the horizon?. Journal of Endocrinological Investigation, 2003, 26, 170-173.	3.3	6
134	Understanding osteoporotic pain and its pharmacological treatment: supplementary presentation. Osteoporosis International, 2018, 29, 2153-2154.	3.1	6
135	A New Era for Chronic Management of Hypoparathyroidism: Parathyroid Hormone Peptides. Frontiers of Hormone Research, 2019, 51, 165-171.	1.0	6
136	How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?. Osteoporosis International, 2021, 32, 1921-1935.	3.1	6
137	Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis?. International Journal of Molecular Sciences, 2021, 22, 10465.	4.1	6
138	Hypoparathyroidism: State of the Art on Cell and Tissue Therapies. International Journal of Molecular Sciences, 2021, 22, 10272.	4.1	6
139	In Vitro Control of Genes Critical for Parathyroid Embryogenesis by Extracellular Calcium. Journal of the Endocrine Society, 2020, 4, bvaa058.	0.2	6
140	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. Nutrients, 2021, 13, 3567.	4.1	6
141	Current treatment approaches for Paget's Disease of Bone. Discovery Medicine, 2010, 10, 209-12.	0.5	6
142	Genetics of hypoparathyroidism and pseudohypoparathyroidism. Journal of Endocrinological Investigation, 2011, 34, 27-34.	3.3	6
143	Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series. Endocrine, 2022, , 1.	2.3	6
144	Conventional Treatment of Hypoparathyroidism. Frontiers of Hormone Research, 2019, 51, 160-164.	1.0	5

#	Article	IF	Citations
145	Study of the Expression and Function of Calcium-Sensing Receptor in Human Skeletal Muscle. International Journal of Molecular Sciences, 2021, 22, 7282.	4.1	5
146	MicroRNAs as Potential Biomarkers in Pituitary Adenomas. Non-coding RNA, 2021, 7, 55.	2.6	5
147	Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. Orphanet Journal of Rare Diseases, 2021, 16, 421.	2.7	5
148	Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1â€“84) treatment. Journal of Endocrinological Investigation, 2022, 45, 1653-1662.	3.3	5
149	Massive intrathoracic lipoma in men1 syndrome. International Journal of Surgery Case Reports, 2015, 6, 247-250.	0.6	4
150	MicroRNAs regulatory networks governing the epigenetic landscape of MEN1 gastroâ€enteroâ€pancreatic neuroendocrine tumor: A case report. Clinical and Translational Medicine, 2021, 11, e351.	4.0	4
151	Polymorphic variants of alkaline phosphatase gene correlate with clinical signs of adult hypophosphatasia?. Osteoporosis International, 2021, 32, 2461-2472.	3.1	4
152	Congenital Metabolic Bone Disorders as a Cause of Bone Fragility. International Journal of Molecular Sciences, 2021, 22, 10281.	4.1	4
153	Bone fragility in patients affected by congenital diseases non skeletal in origin. Orphanet Journal of Rare Diseases, 2021, 16, 11.	2.7	4
154	The role of the orthopaedic surgeon in the prevention of refracture in patients treated surgically for fragility hip and vertebral fracture. Clinical Cases in Mineral and Bone Metabolism, 2014, 11, 31-5.	1.0	4
155	Association between vitamin D and bisphenol A levels in an elderly Italian population: results from the InCHIANTI study. Endocrine Connections, 2022, 11, .	1.9	4
156	Cardiovascular Safety and Effectiveness of Bisphosphonates: From Intervention Trials to Real-Life Data. Nutrients, 2022, 14, 2369.	4.1	4
157	Genetics and pharmacogenetics of estrogen response. Expert Review of Endocrinology and Metabolism, 2007, 2, 503-516.	2.4	3
158	GCM2 Silencing in Parathyroid Adenoma Is Associated With Promoter Hypermethylation and Gain of Methylation on Histone 3. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4084-e4096.	3.6	3
159	Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives. Expert Review of Endocrinology and Metabolism, 2021, 16, 295-307.	2.4	3
160	The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocrine Disorders, 2021, 21, 232.	2.2	3
161	Mediterranean diet adherence and dietary calcium intake in a group of pregnant women: Results of an Italian survey. Food Science and Nutrition, 2021, 9, 3426-3435.	3.4	2
162	ALPLGenotypes in Patients With Atypical Femur Fractures or Other Biochemical and Clinical Signs of Hypophosphatasia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2087-e2094.	3.6	2

#	Article	IF	Citations
163	Phosphatonins: new hormones that control phosphorus homeostasis. Expert Review of Endocrinology and Metabolism, 2008, 3, 513-526.	2.4	1
164	Hyperparathyroidism in MEN1 syndrome: time to operate?. Nature Reviews Endocrinology, 2010, 6, 604-605.	9.6	1
165	Pharmacogenetics of osteoporosis. Expert Review of Endocrinology and Metabolism, 2010, 5, 905-910.	2.4	1
166	Hypoparathyroidism: the hormone replacement therapy is close. Expert Review of Endocrinology and Metabolism, 2012, 7, 255-257.	2.4	1
167	When the government actively faces the burden of osteoporosis: the Italian experience. Archives of Osteoporosis, 2012, 7, 21-24.	2.4	1
168	Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens: response to comments by Chen et al.. Osteoporosis International, 2018, 29, 1219-1220.	3.1	1
169	Genetic Determinants of Inherited Endocrine Tumors: Do They Have a Direct Role in Bone Metabolism Regulation and Osteoporosis?. Genes, 2021, 12, 1286.	2.4	1
170	Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations. Journal of Endocrinological Investigation, 2022, , 1.	3.3	1
171	Genetic models for parathyroid tumorigenesis. Journal of Endocrinological Investigation, 1992, 15, 113-9.	3.3	1
172	Bone phenotypes in multiple endocrine neoplasia type 1: survey on the MEN1 Florentine database. Endocrine Connections, 2022, 11, .	1.9	1
173	Secretin Stimulation Test and Early Diagnosis of Gastrinoma in MEN1 Syndrome: Survey on the MEN1 Florentine Database. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2110-e2123.	3.6	1
174	Estrogens and melanoma: an important clinical question. Expert Review of Endocrinology and Metabolism, 2012, 7, 587-588.	2.4	0
175	AB0831â€…PERSPECTIVE ON THE CLINICAL PRACTICE MANAGEMENT OF HYPOVITAMINOSIS D FROM A MEETING OF ITALIAN EXPERTS. , 2019, , .		0
176	Advances in the management of asymptomatic hyperparathyroidism. F1000 Medicine Reports, 2009, 1, .	2.9	0
177	Role of observational studies in assessing osteoporosis therapies: the REAL study. Clinical Cases in Mineral and Bone Metabolism, 2007, 4, 161-2.	1.0	0
178	Calcaneal quantitative ultrasound as a reliable tool in assessing osteoporosis and its risk factors in a large cohort of the Italian population. Clinical and Experimental Rheumatology, 2004, 22, 553.	0.8	0
179	Reply to Calcifediol Is Not Superior to Cholecalciferol in Improving Vitamin D Status in Postmenopausal Women. Journal of Bone and Mineral Research, 2020, 37, 1413-1415.	2.8	0